Exercise of Options and Total Voting Rights
Updated : 09:46
24 July 2020
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Exercise of Options and Total Voting Rights
Omega Diagnostics (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance testing, announces that it has allotted 50,000 new ordinary shares of 4 pence each in the capital of the Company ("Ordinary Shares") following the exercise of share options by an employee.
Application has been made to the London Stock Exchange for the 50,000 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 30 July 2020.
After Admission, the total number of Ordinary Shares in issue will be 178,203,110 and the total number of voting rights will therefore be 178,203,110. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.The below notification is made in accordance with the requirements of the EU Market Abuse Regulation.
Contacts:
Omega Diagnostics Group PLC | Tel: 01259 763 030 |
Colin King, Chief Executive | |
Kieron Harbinson, Group Finance Director | |
finnCap Ltd | Tel: 020 7220 0500 |
Geoff Nash / Hannah Boros /Teddy Whiley (Corporate Finance) | |
Camille Gochez (ECM) | |
Walbrook PR Limited | Tel: 020 7933 8780 or omega@walbrookpr.com |
Paul McManus | Mob: 07980 541 893 |
Lianne Cawthorne | Mob: 07584 391 303 |
Notification and public disclosure of transactions by Persons Discharging Managerial Responsibilities ("PDMR") and persons closely associated with them ("PCA")
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Mr Prashant Maniar | |||||
2 | Reason for notification | ||||||
a. | Position/Status | Managing Director of Omega Dx (Asia) Pvt. Ltd | |||||
b. | Initial notification/ Amendment | Initial Notification | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | Omega Diagnostics Group Plc | |||||
b. | LEI | 2138007U9P4BTZTYIR92 | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrument | Ordinary shares of 4p each
ISIN: GB00B1VCP282 | |||||
b. | Nature of the transaction | Exercise of Options followed by sale of Shares | |||||
c. | Price(s) and volume(s) | ||||||
Price(s) | Volume(s) | ||||||
18.25p | 50,000 | ||||||
d. | Aggregated information - Aggregated Volume - Price |
50,000 18.25p
| |||||
e. | Date of the transaction | 30 July 2020 | |||||
f. | Place of the transaction | London Stock Exchange | |||||
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.